<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2324">
  <stage>Registered</stage>
  <submitdate>15/04/2009</submitdate>
  <approvaldate>15/04/2009</approvaldate>
  <nctid>NCT00882453</nctid>
  <trial_identification>
    <studytitle>Physical Activity and Fatigue in Early Multiple Sclerosis (MS)</studytitle>
    <scientifictitle>Betaferon Treatment and Exercise Data Gathering IN Early MS</scientifictitle>
    <utrn />
    <trialacronym>BEGIN</trialacronym>
    <secondaryid>BF0601</secondaryid>
    <secondaryid>13853</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Multiple Sclerosis</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Interferon beta-1b (Betaseron, BAY86-5046)

Group 1 - 


Treatment: drugs: Interferon beta-1b (Betaseron, BAY86-5046)
Intravenous therapy according to product information

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Physical Activity and Fatigue</outcome>
      <timepoint>At baseline and at Month 24</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Health-related Quality of Life</outcome>
      <timepoint>At baseline and at Month 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Depression</outcome>
      <timepoint>At baseline and at Month 24</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Multiple sclerosis diagnosed within the last 12 months

          -  Clinically isolated Syndrome (CIS), under Interferon-beta-1b treatment</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>1739</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Many Locations</hospital>
    <postcode> - Many Locations</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bahrain</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Indonesia</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Jordan</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Kazakhstan</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Kuwait</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lebanon</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Oman</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovenia</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Arab Emirates</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bayer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this observational study is to obtain a survey on physical activity in
      patients who for the first time have experienced symptoms which indicate a high risk for
      developing multiple sclerosis (MS) and in patients with recently diagnosed MS, and to obtain
      information on factors potentially influencing the patients' level of activity.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00882453</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bayer Study Director</name>
      <address>Bayer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>